modelBelzutifan
Extends from Pharmacolibrary.Drugs.ATC.L.L01XX74.
Information
| name: | Belzutifan | |
| ATC code: | L01XX74 | route: | oral |
| compartments: | 1 | |
| dosage: | 120 | mg |
| volume of distribution: | 337 | L |
| clearance: | 17 | L/h |
| other parameters in model implementation | ||
Belzutifan is an oral small molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α). It is approved for the treatment of von Hippel-Lindau (VHL) disease-associated renal cell carcinoma, central nervous system hemangioblastomas, and pancreatic neuroendocrine tumors that do not require immediate surgery. The drug is currently approved and in clinical use.
Pharmacokinetics
Pharmacokinetic parameters reported in adult patients with cancer receiving oral belzutifan 120 mg once daily.
References
Marathe, DD, et al., & Jain, L (2023). Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling. CPT: pharmacometrics & systems pharmacology 12(10) 1499–1510. DOI:10.1002/psp4.13028 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37596839
Marathe, DD, et al., & Jain, L (2024). Exposure-Response Analyses for Belzutifan to Inform Dosing Considerations and Labeling. Journal of clinical pharmacology 64(10) 1246–1258. DOI:10.1002/jcph.2459 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38752556
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)